Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis

Biomarkers in Medicine

Volumn 10, Issue 1, 2016, Pages 35-49

  Parnetti, Lucilla ^a   Cicognola, Claudia ^b   Eusebi, Paolo ^a,c   Chiasserini, Davide ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Regional Health Authority of Umbria   (Italy)

Author keywords

cerebrospinal fluid biomarkers; cognitive impairment; disease progression; early diagnosis; motor symptoms; Parkinson's disease; parkinsonisms; prognosis; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HOEHN AND YAHR SCALE; HUMAN; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; OLIGOMERIZATION; PARKINSON DISEASE; PARKINSONISM; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVIEW; SHY DRAGER SYNDROME; SYSTEMATIC REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE; WESTERN BLOTTING; CEREBROSPINAL FLUID; CHEMISTRY; PATHOPHYSIOLOGY;

ALPHA-SYNUCLEIN; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PARKINSON DISEASE; PROGNOSIS;

EID: 84951771245     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.107     Document Type: Review

References (54)

1. Parnetti L, Castrioto A, Chiasserini D et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nature Rev. Neurol, 9(3), 131-140 (2013).
2. Alonso-Navarro H, Jimenez-Jimenez FJ, Garcia-Martin E, Agundez JA. Genomic and pharmacogenomic biomarkers of Parkinson's disease. Curr. Dru Metabol. 15(2), 129-181 (2014).
3. Pfeiffer RF. Non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. doi:10.1016/j. parkreldis.2015.09.004 (2015) (Epub ahead pf print).
4. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson's disease. Mov. Disord. 30(11), 1490-1504 (2015).
5. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837-844 (2008).
6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387-392 (2003).
7. Parkinson's Progression Markers Initiative. http://www.ppmi-info.org
8. The Parkinson's Progression Marker Initiative (PPMI) - assessment of clinical, imaging and CSF PD biomarkers. http://www.ppmi-info.org
9. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 10(11), 1015-1025 (2011).
10. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321), 2045-2047 (1997).
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 388(6645), 839-840 (1997).
12. El-Agnaf OM, Salem SA, Paleologou KE et al. Alphasynuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13), 1945-1947 (2003).
13. Borghi R, Marchese R, Negro A et al. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287(1), 65-67 (2000).
14. Mollenhauer B. Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease? Parkinsonism Relat. Disord. 20(Suppl. 1), S76-S79 (2014).
15. Tokuda T, Salem SA, Allsop D et al. Decreased alphasynuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006).
16. Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26(8), 1428-1435 (2011).
17. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33(2), 430 e431-e433 (2012).
18. Compta Y, Valente T, Saura J et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-alphasynuclein in premotor, motor and dementia stages of Parkinson's disease. J. Neurol. 262(2), 294-306 (2015).
19. Magdalinou NK, Paterson RW, Schott JM et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatr. doi:10.1136/jnnp-2014-309562 (2015) (Epub ahead of print).
20. Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 84(1), 57-63 (2015).
21. Kruse N, Mollenhauer B. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human alpha-synuclein in cerebrospinal fluid. J. Immunol. Method. doi:10.1016/j.jim.2015.08.003 (2015) (Epub ahead of print).
22. Tokuda T, Qureshi MM, Ardah MT et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75(20), 1766-1772 (2010).
23. Parnetti L, Chiasserini D, Persichetti E et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov. Disord. 29(8), 1019-1027 (2014).
24. Vaikath NN, Majbour NK, Paleologou KE et al. Generation and characterization of novel conformation-specific monoclonal antibodies for alpha-synuclein pathology. Neurobiol. Dis. 79, 81-99 (2015).
25. Fagerqvist T, Lindstrom V, Nordstrom E et al. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 126(1), 131-144 (2013).
26. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713-726 (2010).
27. Wang Y, Shi M, Chung KA et al. Phosphorylated alphasynuclein in Parkinson's disease. Sci. Transl. Med. 4(121), 121ra120 (2012).
28. Bidinosti M, Shimshek DR, Mollenhauer B et al. Novel onestep immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J. Biol. Chem. 287(40), 33691-33705 (2012).
29. van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD. Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur. J. Neurol. 21(3), 388-394 (2014).
30. Aasly JO, Johansen KK, Bronstad G et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6, 248 (2014).
31. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiol. Aging 36(1), 476-484 (2015).
32. Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69(11), 1445-1452 (2012).
33. Hu Y, Yu SY, Zuo LJ et al. Parkinson disease with REM sleep behavior disorder: features, alpha-synuclein, and inflammation. Neurology 84(9), 888-894 (2015).
34. Kang JH, Irwin DJ, Chen-Plotkin AS et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70(10), 1277-1287 (2013).
35. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315-325 (2008).
36. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10(3), 230-240 (2011).
37. Mollenhauer B, Trautmann E, Taylor P et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48 (2013).
38. Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A. CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat. Disord. 20(4), 382-387 (2014).
39. Ohrfelt A, Grognet P, Andreasen N et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders - a marker of synapse loss? Neurosci. Lett. 450(3), 332-335 (2009).
40. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 7(4), 215-222 (2011).
41. Parnetti L, Farotti L, Eusebi P et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease. Front. Aging Neurosci. 6, 53 (2014).
42. Reesink FE, Lemstra AW, van Dijk KD et al. CSF alphasynuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 22(1), 87-95 (2010).
43. Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69(3), 570-580 (2011).
44. Stewart T, Liu C, Ginghina C et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 184(4), 966-975 (2014).
45. Stewart T, Sossi V, Aasly JO et al. Phosphorylated alphasynuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol. Commun. 3, 7 (2015).
46. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26(3), 213-216 (2012).
47. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol. 126(5), 683-697 (2013).
48. Wang H, Wang K, Xu W et al. Cerebrospinal fluid alphasynuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. J. Neurochem. 122(1), 19-23 (2012).
49. Wennstrom M, Surova Y, Hall S et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8(1), e53250 (2013).
50. Gao L, Tang H, Nie K et al. Cerebrospinal fluid alphasynuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci. 125(9), 645-654 (2015).
51. Sako W, Murakami N, Izumi Y, Kaji R. Reduced alphasynuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov. Disord. 29(13), 1599-1605 (2014).
52. del Campo M, Mollenhauer B, Bertolotto A et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers Med. 6(4), 419-430 (2012).
53. Laurens B, Constantinescu R, Freeman R et al. Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol. Dis. 80, 29-41 (2015).
54. Lleo A, Cavedo E, Parnetti L et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Rev. Neurol. 11(1), 41-55 (2015).